|
|
||||||||
LETTER TO THE EDITOR |
A) of reduced folate carrier gene in trisomy 21
ISAB - Unity QUASH
Laboratory of Nutritional Genomics
BP.30313
Rue Pierre Waguet
60026-Beauvais
France
E-mail: abalo.chango{at}isab.fr
Faculty of Medicine
Laboratory of Medical Biochemistry
Vandoeuvre-Les-Nancy
France
Jerome Lejeune Institute
Paris
France
Dear Sir:
The reduced folate carrier gene (RFC1 or SLC19A1) located on chromosome 21 (21q22.3) codes for the reduced folate carrier, which is responsible for 5-methyltetyrahydrofolate internalization within cells. We published earlier the 80G
A single-nucleotide polymorphism (SNP) in human reduced folate carrier cDNA and hypothesized that it influences folate metabolism or the plasma total homocysteine concentration (1). The SNP 80G
A polymorphism (rs1051266; http://www.ncbi.nlm.nih.gov at the SNP database) is a guanine-to-adenine exchange at nucleotide 80 in RFC1 cDNA. Because of the extra copy of chromosome 21 in persons with trisomy 21, or Down syndrome, a dosage effect of RFC1 and a functional effect of the SNP 80G
A polymorphism may contribute to a imbalance of one-carbon-derived metabolites and DNA methylation. Allelic ratios are 3:0, 2:1, 1:2, and 0:3 for the 80GGG, 80GGA, 80GAA, and 80AAA genotypes, respectively, in trisomy 21 compared with 2:0, 1:1, and 0:2 for the 80GG, 80GA, 80AA genotypes, respectively, in control subjects.
In a study published in this issue of the Journal, we analyzed the 80G
A genotype distribution in 160 persons (87 men and 73 women) aged 26 ± 4 y (
± SD; range: 1546 y) with full trisomy 21 confirmed by karyotype and in 160 healthy, unrelated control subjects (2). With the standard restriction fragment length polymorphism method using the HhaI (or CfoI) restriction enzyme (1, 3), we were not able to distinguish heteroallelic individuals containing 1 or 2 copies of each allele among the persons with Down syndrome. We have now applied the pyrosequencing technology (4) to determine SNP genotypes in persons with trisomy 21.
The principle of pyrosequencing is based on the polymerization of single-stranded amplified DNA fragments and the detection of de novo incorporation of nucleotides, which leads to the generation of visible light in proportion to the number of incorporated nucleotides (Figure 1
). Briefly, DNA samples were amplified by polymerase chain reaction with the sense primer HsRFC 4.3 5'-TGC AGA CCA TCT TCC AAG G-3' and the antisense primer HsRFC 4.3 5'-CCA TGA AGC CGT AGA AGC-3'. The amplified DNA samples were purified by using streptavidin-Sepharose HP beads (Amersham Biosciences, Orsay, France) and a pyrosequencing sample preparation kit (Pyrosequencing AB, Uppsala, Sweden) according to the manufacturer's instructions. Purified samples were run on a PSQ 96MA instrument containing a pyrosequencing cartridge filled with dATP
S, dTTP, dCTP, dGTP, substrate, and enzyme as supplied in a PSQ reagent kit (Pyrosequenring). The 4 nucleotides are added stepwise to the primed DNA template. Analysis of sequences was performed automatically by the ALLELE QUANTIFICATION software (Pyrosequencing). The intensity of the light signal is directly proportional to the number of nucleotides incorporated. Genotypes were determined by comparison of the peak heights of allele positions with the theoretical results predicted by the software.
|
ACKNOWLEDGMENTS
Funded by the Jerome Lejeune Foundation, Paris. We are grateful to Severine Barry-Charret and Severine Ferre for expert laboratory analysis.
AC was the principal investigator and was responsible for developing the pyrosequencing technique and writing the manuscript. NFE contributed to collecting samples and analyzing the laboratory data. HB was the initial protocol designer responsible for collecting and managing the patients and samples during the study. JPN was the co-principal investigator and is the head of the medical biochemistry research group. FW developed the Agrohealth research program in the ISAB. None of the authors had any conflicts of interest.
REFERENCES
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |